Study of ICP-490 for non-Hodgkin lymphoma that has returned or not responded to treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an investigational drug called ICP-490 for people with non-Hodgkin lymphoma that has come back or hasn't improved after prior treatments. The study checks if the drug is safe, tolerable, and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your lymphoma has come back or has not improved after previous treatments.
- You must have measurable disease (tumors that can be seen on scans).
- You must be able to care for yourself (performance status 0-2).
- Your organs must be working well enough (kidney, liver, etc.).
- You must expect to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
This trial tests an experimental drug (HSK47977) to see how it works in people with non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to understand how the drug is processed by the body, its safety, and whether it can help shrink tumors.
This early-phase (Phase 1) study tests ICP-248 in people with certain B-cell cancers that have come back (relapsed) or did not respond to prior treatment (refractory). The goal is to learn the safest dose and whether it can help shrink or control the cancer.
This Phase 1/2 study tests an injection called GNC-038 in people with non-Hodgkin’s lymphoma that has come back or is resistant to treatment. It aims to see how well the drug works and how safe it is for this group.
This trial tests a new drug called ICP-248 for people with mantle cell lymphoma that has returned or not responded to previous treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug, GNC-035, for people with non-Hodgkin's lymphoma that has come back (relapsed) or stopped responding to standard treatments (refractory). The goal is to see if GNC-035 can help when other options haven't worked.
Hear when a new Relapsed or Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.